HOLX - Comprehensive Filing Intelligence

FYNone•10-Q•Filed Jan 29, 2026

6.0/10

Filing Health:GOOD

Solid fundamentals with minor concerns to monitor

Executive Summary

Revenue declined in Diagnostics and Breast Health due to specific product issues and market normalization, while GYN Surgical and Skeletal Health showed growth, boosted by acquisitions and recovery.. Gross margins were negatively impacted by increased tariff costs and lower sales of high-margin products, with specific concerns noted for Brevera 9 Gauge Needles recall.. A settlement agreement was executed on January 7, 2026, to resolve the BioZorb litigation for an amount fully covered by insurance, with the company expecting no financial liability.. Diagnostics revenue decreased 0.8% due to lower molecular diagnostic sales.

Top Concerns

!Revenue declined in Diagnostics and Breast Health due to specific product issues and market normalization, while GYN Surgical and Skeletal Health showed growth, boosted by acquisitions and recovery.
!Gross margins were negatively impacted by increased tariff costs and lower sales of high-margin products, with specific concerns noted for Brevera 9 Gauge Needles recall.
!Acquisition-related charge of $22.4 million included acceleration of unvested stock options for Gynesonics acquisition, which is a one-time cost but indicates potential for significant equity payouts upon acquisitions.
!A settlement agreement was executed on January 7, 2026, to resolve the BioZorb litigation for an amount fully covered by insurance, with the company expecting no financial liability.
!Proposed Acquisition Uncertainty (high)

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

7.0/10

Management tone is balanced with focus on decrease in molecular diagnostics business primarily due to normalization of covid-19 cases and greater use of rapid tests.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

7.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is low with 0 in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows proposed acquisition uncertainty as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

5.0/10

Segment health analysis shows Skeletal Health as strongest performer while Diagnostics lags.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.